New website is here!
Create an account to use the new features. Feel free to leave us feedback, constructive criticism welcome!
ARX's Principal Activity is the designing and selling regenerative healing products.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-15.51%|
|vs ASX 200 (1yr)||-20.65%|
|ASX Rank||549 of 2,466|
|Sector Rank||38 of 177|
Aroa Biosurgery Limited (ARX) is a soft tissue regeneration company focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. It participates in the wound care and surgical reconstruction markets. Its products currently for sale in the key US market target chronic wounds and soft tissue reconstruction including, hernia, breast reconstruction and trauma/limb salvage/ tumour surgery.
No incorporation details available.
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Mr John Flower Diddams||Non-Executive Director||Oct 2015||
Mr John Flower Diddams
Mr Diddams has knowledge and practical experience in the application of Australian corporations law, ASX Listing Rules, international accounting standards, and corporate governance principles. Over the past 25 years he has managed the processes to raise capital, perform due diligence, and seek ASX listing for a number of enterprises, including IPOs for a range of offerings. These include oil and gas interests, food and retail, a fine wool processing plant, an telephony product, a biotech company, an Internet advertising initiative, a dental device for snoring and sleep apnoea, an indoor skydiving company, the New Zealand developer of the Martin Jetpack, a healthy fast food chain, and Skydive the Beach Group Limited (now Experience Co Limited). He is a Non-Executive Director of Aroa Biosurgery Limited, a New Zealand based company that develops and markets proprietary soft tissue regenerative products, and Surf Lakes Holdings Limited, a Gold Coast based business with patented technology for recreational wave generation.
|Mr Steven (Steve) Barnard Engle||Non-Executive Director||Apr 2015||
Mr Steven (Steve) Barnard Engle
Mr Engle has over 20 years of executive leadership experience with public biotech companies developing products in metabolic, autoimmune, oncologic and infectious disease areas. He is the Chief Executive Officer of CohBar, a clinical stage biotechnology company developing mitochondria-based therapeutics to treat age-related diseases and extend healthy lifespan. Before joining CohBar, Steven served as CEO of Averigon Consulting, an advisory firm to the life science industry, supporting companies through product partnering, regulatory planning, investor relations and executive management. Previously, he was Chairman and CEO of XOMA Corporation, a leader in the development of therapeutic antibodies and antibody technologies. Prior to XOMA, Steven served as Chairman and CEO of La Jolla Pharmaceutical Company. Earlier, he served as Vice President of Marketing for Cygnus, a drug delivery systems company, where he helped to gain FDA approval and to launch Nicotrol for smoking cessation. Steven is the non-executive Chairman of the Board of Prescient Therapeutics Ltd., an ASX listed clinical stage oncology company, and a director of the board of Author-it Software Corporation, a developer of authoring information solutions for pharmaceutical and biotechnology companies. He is a former director of industry associations, BIO, BayBio and BIOCOM, and was a Member of the board of the Lupus Foundation of America.
|Mr John Richard Pinion II||Non-Executive Director||Feb 2015||
Mr John Richard Pinion II
Mr Pinion has over 26 years of experience in biologic, small molecule pharmaceutical, gene therapy and device operations across Asia, Europe and the Americas. He joined Ultragenyx in July 2015 and currently holds the role of EVP, Translational Sciences and Chief Quality Operations Officer. He provides leadership for Ultragenyx's translational sciences functions which includes Pharmacology and Toxicology, Research and Bioanalytical Development, as well as GxP Quality and Compliance and CMC Analytical Development and QC. In the ten years prior to joining Ultragenyx, John has held roles of increasing responsibility at Genentech (subsequently Roche post Genentech acquisition), departing the organization as Senior Vice President and Global Head of Quality and Compliance for Pharma Technical Operations based in Basel, Switzerland. Previous to Genentech, John spent 17 years in operational and senior leadership roles in Baxter International's Renal, Bioscience, Parenterals and Device divisions. He is also member of the Risk Committee of the company.
|Mr James (Jim) Neil McLean||Non-Executive Chairman, Non-Executive Director||Aug 2011||
Mr James (Jim) Neil McLean
Non-Executive Chairman, Non-Executive Director
Mr McLean has gained 25 years experience serving as either Chair, Director, or an executive of research and technology businesses for both commercial and New Zealand Government organisations. In addition to Aroa, current appointments include Chair of Prevar Limited, R J Hill Laboratories Limited and Information Tools Limited. He was Chair of the New Zealand Institute of Plant & Food Research and Chair of its predecessor HortResearch, as well as several private businesses and start-up companies. He served on the board of the then Foundation for Research, Science, and Technology including five years as deputy Chair. Jim was an executive and director of Genesis Research & Development Corporation Limited during its early stages through public listing. Before focusing in science and technology businesses, Jim held management positions with an international manufacturing business and spent thirteen years as a partner at chartered accountants, EY. His time at EY was focused on business strategy and included two years' secondment to EY's Washington DC office. He is a member of the Risk Committee.
|Mr Philip John McCaw||Non-Executive Director||Mar 2008||
Mr Philip John McCaw
Mr McCaw is the Founding Partner of Movac, one of New Zealand's Venture Capital funds. Phil has over 20-years experience investing into New Zealand technology companies and helping to guide their growth. Phil was an early investor in Trade Me, New Zealand's on-line trading community, which was sold to Fairfax in 2006. He was also an early investor into PowerByProxi, a wireless power technology spin-out from Auckland University, which was sold to Apple in 2018. Outside of Movac, Phil remains an angel investor and maintains a personal angel investment portfolio. He is a advocate for the development of the entrepreneurial and early-stage investment eco-system in New Zealand and was the past Chair of the Angel Association of New Zealand; a founding investor in the Lightning Lab technology accelerator; and a founding investor in the Kiwi Landing Pad in San Francisco. Prior to starting Movac Phil spent 10-years with Deloitte Consulting working in New Zealand and the USA.
|Mr Brian Roderick Ward||Chief Executive Officer, Managing Director||Sep 2007||
Mr Brian Roderick Ward
Chief Executive Officer, Managing Director
Mr Ward has held senior corporate roles in life sciences and health care companies over the last 25 years. He has management experience in life science companies spanning clinical, technical, sales, marketing, corporate development and strategy having worked for a number of multinationals including Baxter, Beecham and SmithKline Beecham throughout the world. He has managed investments into New Zealand technology companies for the Foundation for Research Science and Technology, served as the founding CEO of NZBio, and has sat on a number of government and industry expert panels.
ARX directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|09/12/20||John Diddams||Buy||+165,000||$0.107||$17,737||Exercise of options|
|09/12/20||John Diddams||Exercise||165,000||$0.107||$17,737||Exercise of options|
The current holdings of ARX directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Steven (Steve) Engle||01/04/2015||226,533||N/A||879,000||N/A|
|John Pinion II||01/02/2015||472,500||N/A||879,000||N/A|
|James (Jim) McLean||10/08/2011||2,572,308||N/A||307,200||N/A|
Data supplied by Morningstar and accurate on Jul 22, 2020.
It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.
All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).
|Brian Ward and Tracey Ward <ARAWAI No 2 A/C>||33,125,800||11.04%|
|Movac Fund 3 Lp||25,841,850||8.61%|
|Phill Mccaw <Mcsyth Capital Investment A/C>||16,722,425||5.57%|
|Richard Abbott <Jester 002 Investment>||11,579,775||3.86%|
|Aspre Nz Seed Fund Ltd||10,332,407||3.44%|
|Sparkbox Investment Ltd||10,085,633||3.36%|
|National Nominees Limited||9,835,163||3.28%|
|HSBC Custody Nominees (Australia) Limited||9,227,800||3.08%|
|BNP Paribas Noms Pty Ltd <Drp>||8,450,700||2.82%|
|Firetrail Investment Pty Ltd <Firear A/C>||6,374,625||2.12%|
|K One W One <No 3 > Ltd||6,359,475||2.12%|
|Mark Ritcher <Ritcher Investment A/C>||6,016,350||2.00%|
|Mesynthes Nominee Ltd||5,354,175||1.78%|
|HSBC Custody Nominees (Australia) Limited A/C 2||4,919,267||1.64%|
|Sharon Bryant <Ot Investment A/C>||4,815,198||1.60%|
|Washington H Soul Pattinson and Company Ltd||4,583,325||1.53%|
|K One W One Ltd||3,881,342||1.29%|
|Movac Sidecar Fund Lp||3,864,750||1.29%|
|Holding Size||1 - 1,000||1,001 - 5,000||5,001 - 10,000||10,001 - 100,000||100,001+||Total|
|No. of Shareholders||9||218||276||707||137||1,347|
No Substantial Shareholders for ARX in our database.
No buy transactions reported by Substantial Shareholders in the past 12 months.
No sell transactions reported by Substantial Shareholders in the past 12 months.
|Year||Closing Price||Last Trade|
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.